Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study with IN-001 in healthy volunteers

Next Previous
X
Search
Trial Profile

A Phase 1 study with IN-001 in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dipivefrine (Primary) ; Epinephrine
  • Indications Anaphylaxis
  • Focus Adverse reactions

    • Most Recent Events

    • 05 Nov 2020 New trial record
    • 29 Oct 2020 According to an Insignis Therapeutics media release, if this study is successful, under the 505(b)(2) regulatory pathway, Insignis and HLK Pharmacin would begin preparations to initiate a pivotal study in the second half of 2021.
    • 29 Oct 2020 According to an Insignis Therapeutics media release, the company and HLK Pharmacin announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN-001, an oral formulation of an epinephrine prodrug for life-saving treatment of allergic reactions, including anaphylaxis. Under this IND, the companies are prepared to initiate a Phase 1 study this quarter and intends to have clinical data in first half of 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top